Lee, Kyung-Hun

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 2,175

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Wang-Gillam, A., Li, C.-P., Bodoky, G., Dean, A., Shan, Y.-S., Jameson, G., Macarulla, T., Lee, K.-H., Cunningham, D., Blanc, J. F., et al. (2016) · The Lancet

Pancreatic and Hepatic Oncology ResearchCancer Treatment and Pharmacology

Cited by 1,222

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

Lee, M. S., Ryoo, B.-Y., Hsu, C.-H., Numata, K., Stein, S., Verret, W., Hack, S. P., Spahn, J., Liu, B., Abdullah, H., et al. (2020) · The Lancet Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 562

Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis

Keam, B., Im, S.-A., Lee, K.-H., Han, S.-W., Oh, D.-Y., Kim, J. H., Lee, S.-H., Han, W., Kim, D.-W., Kim, T.-Y., et al. (2011) · Breast Cancer Research

Breast Cancer Treatment StudiesBreast Lesions and Carcinomas

Cited by 235

Longitudinal Association of Poor Sleep Quality With Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer

Jung, D., Lee, K.-M., Kim, W.-H., Lee, J.-Y., Kim, T.-Y., Im, S.-A., Lee, K.-H., Spiegel, D., & Hahm, B.-J. (2016) · Psychosomatic Medicine

Nausea and vomiting managementCancer survivorship and care

Cited by 33

Abstract CT071: Talazoparib (TALA) in germline BRCA1/2 (g BRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): Final overall survival (OS) results from randomized Phase 3 EMBRACA trial

Litton, J. K., Hurvitz, S. A., Mina, L. A., Rugo, H. S., Lee, K.-H., Gonçalves, A., Diab, S., Woodward, N., Goodwin, A., Yerushalmi, R., et al. (2020) · Cancer Research

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 10